Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3)

Vaccine

Volumn 24, Issue 23, 2006, Pages 4914-4926

  Sanchez, Violette ^a   Gimenez, Sophie ^a   Tomlinson, Brian ^b   Chan, Paul K S ^b   Thomas, G Neil ^b   Forrat, Remi ^a   Chambonneau, Laurent ^a   Deauvieau, Florence ^a   Lang, Jean ^a   Guy, Bruno ^a  

^a SANOFI PASTEUR   (France)

^b Drug Development Center   (Hong Kong)

Author keywords

Cellular immunity; Clinical trial; HLA; HLA B60; Live dengue vaccine

Indexed keywords

ALPHA INTERFERON; CD8 ANTIGEN; DENGUE VACCINE; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HLA B60 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; LIVE VACCINE; LIVER ENZYME; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERO ADAPTED DENGUE SEROTYPE 3 VACCINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADAPTIVE IMMUNITY; ADULT; ANIMAL CELL; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENGUE; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FLAVIVIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; INNATE IMMUNITY; LEUKOPENIA; LYMPHOCYTOPENIA; MALAISE; MALE; NEUTROPHILIA; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TH1 CELL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VACCINATION; VERO CELL; VIRUS INFECTION;

ADULT; ANIMALS; CERCOPITHECUS AETHIOPS; CYTOKINES; DENGUE; FEMALE; FLAVIVIRUS; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; MALE; VACCINES, ATTENUATED; VERO CELLS; VIRAL VACCINES;

EID: 33646866323     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.03.066     Document Type: Article

References (42)

1. Mairuhu A.T., Wagenaar J., Brandjes D.P., and van Gorp E.C. Dengue: an arthropod-borne disease of global importance. Eur J Clin Microbiol Infect Dis 23 (2004) 425-433
2. Hombach J., Barrett A.D., Cardosa M.J., Deubel V., Guzman M., Kurane I., et al. Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health. 26-27 April 2004, Bangkok, Thailand. Vaccine 23 (2005) 2689-2695
3. Sabchareon A., Lang J., Chanthavanich P., et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 66 (2002) 264-272
4. Sabchareon A., Lang J., Chanthavanich P., et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 23 (2004) 99-109
5. Rothman A.L., Kanesa-thasan N., West K., Janus J., Saluzzo J.F., and Ennis F.A. Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine. Vaccine 19 (2001) 4694-4699
6. Halstead S.B., and Marchette N.J. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii. Am J Trop Med Hyg 69 6 Suppl. (2003) 5-11
7. Sanchez V., Hessler C., DeMonfort A., Lang J., and Guy B. Comparison by flow cytometry of immune changes induced in human monocyte-derived dendritic cells upon infection with Dengue 2 live attenuated vaccine or 16681 parental strain. FEMS Immunol Med Microbiol 46 1 (2006) 113-123
8. Mangada M.M., Endy T.P., Nisalak A., et al. Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren. J Infect Dis 185 (2002) 1697-1703
9. Rothman A.L. Dengue: defining protective versus pathologic immunity. J Clin Invest 113 (2004) 946-951
10. Mangada M.M., and Rothman A.L. Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol 175 4 (2005) 2676-2683
11. Mangada M.M., Ennis F.A., and Rothman A.L. Quantitation of dengue virus specific CD4+ T cells by intracellular cytokine staining. J Immunol Methods 284 (2004) 89-97
12. Osatomi K., and Sumiyoshi H. Complete nucleotide sequence of dengue type 3 virus genome RNA. Virology 176 2 (1990) 643-647
13. Mongkolsapaya J., Dejnirattisai W., Xu X.N., et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 9 (2003) 921-927
14. McKee Jr. K.T., Bancroft W.H., Eckels K.H., Redfield R.R., Summers P.L., and Russell P.K. Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers. Am J Trop Med Hyg 36 (1987) 435-442
15. Gwinn W., Sun W., Innis B.L., Caudill J., and King A.D. Serotype-specific T(H)1 responses in recipients of two doses of candidate live-attenuated dengue virus vaccines. Am J Trop Med Hyg 69 6 Suppl. (2003) 39-47
16. Mathew A., Kurane I., Green S., et al. Impaired T cell proliferation in acute dengue infection. J Immunol 162 (1999) 5609-5615
17. Zivna I., Green S., Vaughn D.W., et al. T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity. Immunology 168 (2002) 5959-5965
18. Chaturvedi U.C., Agarwal R., Elbishbishi E.A., and Mustafa A.S. Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis. FEMS Immunol Med Microbiol 28 (2000) 183-188
19. Pacsa A.S., Agarwal R., Elbishbishi E.A., Chaturvedi U.C., Nagar R., and Mustafa A.S. Role of interleukin-12 in patients with dengue hemorrhagic fever. FEMS Immunol Med Microbiol 28 (2000) 151-155
20. Nguyen T.H., Lei H.Y., Nguyen T.L., et al. Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J Infect Dis 189 (2004) 221-232
21. Gagnon S.J., Mori M., Kurane I., et al. Cytokine gene expression and protein production in peripheral blood mononuclear cells of children with acute dengue virus infections. J Med Virol 67 (2002) 41-46
22. Raghupathy R., Chaturvedi U.C., Al-Sayer H., et al. Elevated levels of IL-8 in dengue hemorrhagic fever. J Med Virol 56 (1998) 280-285
23. Libraty D.H., Endy T.P., Houng H.S., et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 185 (2002) 1213-1221
24. Kurane I., Innis B.L., Hoke Jr. C.H., Eckels K.H., Meager A., Janus J., et al. T cell activation in vivo by dengue virus infection. J Clin Lab Immunol 46 (1995) 35-40
25. Shresta S., Kyle J.L., Robert Beatty P., and Harris E. Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice. Virology 319 (2004) 262-273 Related Articles, Links
26. Rothman A.L., and Ennis F.A. Immunopathogenesis of Dengue hemorrhagic fever. Virology 257 (1999) 1-6
27. Kurane I., and Ennis F.A. Production of interferon alpha by dengue virus-infected human monocytes. J Gen Virol 69 (1988) 445-449
28. Kurane I., Innis B.L., Nimmannitya S., Nisalak A., Meager A., and Ennis F.A. High levels of interferon alpha in the sera of children with dengue virus infection. Am J Trop Med Hyg 48 (1993) 222-229
29. Diamond M.S., Roberts T.G., Edgil D., Lu B., Ernst J., and Harris E. Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol 74 (2000) 4957-4966
30. Pichyangkul S., Endy T.P., Kalayanarooj S., et al. A blunted blood plasmacytoid dendritic cell response to an acute systemic viral infection is associated with increased disease severity. J Immunol 171 (2003) 5571-5578
31. Green S., Vaughn D.W., Kalayanarooj S., et al. Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity. J Med Virol 59 (1999) 329-334
32. Simmons C.P., Dong T., Chau N.V., et al. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J Virol 79 (2005) 5665-5675
33. Zivny J., DeFronzo M., Jarry W., Jameson J., Cruz J., Ennis F.A., et al. Partial agonist effect influences the CTL response to a heterologous dengue virus serotype. J Immunol 163 (1999) 2754-2760
34. Loke H., Bethell D.B., Phuong C.X., et al. Strong HLA class I-restricted T cell responses in dengue hemorrhagic fever: a double-edged sword?. J Infect Dis 184 (2001) 1369-1373
35. Stephens H.A., Klaythong R., Sirikong M., et al. HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. Tissue Antigens 60 (2002) 309-318
36. Seet R.C.S., Ooi E.E., Wong H.B., and Paton N.I. An outbreak of primary dengue infection among migrant Chinese workers in Singapore characterized by prominent gastrointestinal symptoms and a high proportion of symptomatic cases. J Clin Virol 33 (2005) 336-340
37. Guirakhoo F., Pugachev K., Zhang Z., et al. Safety and efficacy of chimeric Yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 78 (2004) 4761-4775
38. Monath T.P., Guirakhoo F., Nichols R., et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 188 (2003) 1213-1230
39. Monath T.P., McCarthy K., Bedford P., et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20 (2002) 1004-1018
40. Fox J.P., and Penna H.A. Befavior of 17D Yellow Fever virus in rheus monkeys. Relation to substrain, dose and neural or extraneural inoculation. Am J Hyg 38 (1943) 152-172
41. Durbin A.P., Whitehead S.S., McArthur J., et al. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 191 (2005) 710-718
42. Guy B., Chanthavanich P., Gimenez S., et al. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 22 (2004) 3563-3574